二重特異性抗体の世界市場及びパイプライン分析

◆英語タイトル:Global Bispecific Antibody Market & Clinical Pipeline Insight 2020
◆商品コード:KUIK60801
◆発行会社(調査会社):KuicK Research
◆発行日:2016年7月
◆ページ数:213
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥266,400見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥532,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

With revolutionization in the medicinal sector and more of inclination towards personalized therapy, the medical world is also witnessing the emergence of advanced analogues of monoclonal antibodies called as Bispecific monoclonal antibodies. As the name signifies the molecules possess “dual specificity”.The licensing of the first monoclonal antibody for clinical use dates back to 1986, since then almost 70 therapeutic monoclonal antibodies (MAbs) have been approved throughout the world along with several antibody-related products (e.g., Fc-fusion proteins) making MAbs and related products a dominant component of the biopharmaceutical market, generating revenues of several billion dollars. The approach and specificity of these molecules is no doubt gaining the interest of numerous scientists, pharma, biotechnological companies, research laboratories as well as academic institutions adding to everyday improvement in the biological, physical, chemical and bio-chemical aspects of its action and functioning making the segment more interesting.

With coming of the new technology and more of research in this segment around 50 different formats of bispecific antibody production have been discovered and patented by big pharma ventures. Production of CrossMabs, Diabodies, Nano bodies, Bispecific T-cell engager antibodies (BiTEs), dual-variable-domain immunoglobulin (DVD-Ig™) are some of the most employed and significant techniques. These molecules two distinct binding specificities also have shown great potential for a wide range of clinical applications which includes targeting agents for in vitro and in vivo immunodiagnosis, therapy and for improving immunoassays. They have proven themselves as promising molecules for targeting cytotoxic effector cells, delivering radionuclides, toxins or cytotoxic drugs to specific targets, particularly tumor cells. Much more stills needs to be unravelled making this sector a huge matter of interest.

The applications of these molecules are as wide as the approaches of their development. They are being developed to tackle the plethora of diseases ranging from different cancers (Prostate, Breast, Colon, Squamous cell carcinomas) to non-oncological segment including various chronic inflammatory diseases such as Rheumatoid arthritis etc. Their multifactorial approach to deal with a disease is making them for acceptable as a player of future health market as most of the disease are multifactorial and require treatment with a combination of drugs. Development of single molecule with all the desirable approaches is no doubt a great driving factor when seen from patient compliance view.
Moreover, it has been observed that a single molecule can heal more than one disease and nothing more can than this factor make a pharmaceutical venture to invest in Research and Development of this wonder molecule. As developing and patenting a single agent for multiple diseases is for sure a matter of huge profit for them. Following years of research and development (R&D), the first trifunctional antibody Catumaxomab (Removab®) was approved in 2009. Another BsAb Blinatumomab (Blincyto) marketed by Amgen entered the market in December 2014 and several more AMG-110, ABT-122, SAR156597 etc. are in clinical trials.

The pipeline of bispecific antibodies seems to be extremely rich with more than 100 proposed drugs in trials with most of them being in their Preclinical trials. Most of these drugs are propagated to enter the market in the coming 5 to 6 years, occupying a huge segment of health market. The phase is stipulated to swirl the medical world as this will for sure lead to more investments in this direction. The major challenges associated are the monetary restrictions for both the manufacturers as well as the consumers. Everything novel in medical sector comes with a huge price tag and this was proved by extensively costly therapy of Blinatumomab, which costed $178,000 per two-cycles making it unachievable for the common patients. Other associated challenges include stringent regulatory guidelines, conduction of clinical trials and long duration of research associated.

This report extensively covers the major events from the infancy to the present status of the Bispecific antibodies. It gives a purposeful outlook of the bright future of this wonder molecule which is sure to establish its niche in the coming years; as the abnormalities it is proposed to deal with along with the ways to mitigate them is proportionately too high to be ignored.

“Global Bispecific Antibody Market & Clinical Pipeline Insight 2020” Report Highlights:
• Overview of Bispecific Antibody
• Mechanism of Action of Bispecific Antibody
• Design & Engineering of Bispecific Antibodies
• Applications of Bispecific Antibodies
• Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
• Global Bispecific Antibodies Clinical Pipeline: 123 Bispecific Antibodies
• Marketed Bispecific Antibodies: Blinatumomab (Blincyto) & Catumaxomab (Removab)

【レポートの目次】

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism of Action of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removab®)
3.2 Blinatumomab

4. The Design & Engineering of Bispecific Antibodies
4.1 The Design & Engineering of IgG like Bispecific Antibodies
4.1.1 Quadroma (Hybrid Hydromas) Approach
4.1.2 “Knobs Into Holes” Approach
4.1.3 CrossMab Approach
4.1.4 Dual-Variable-Domain Immunoglobulin Approach
4.2 Small Bispecific Antibodies
4.2.1 Bispecific Diabodies
4.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

5. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

6. Applications of Bispecific Antibodies
6.1 BsMAb for Diagnosis of Infectious Diseases
6.1.1 Diagnosis of Bacterial Infections
6.1.2 Diagnosis of Viral Infections
6.2 BsMAb for Cancer Diagnostic
6.3 BsAbs Blocking Signaling Pathways
6.4 BsAbs Targeting Tumor Angiogenesis
6.5 Specific Delivery of Effector Compounds to Targets
6.6 Bispecific Antibodies & Gene Therapy

7. Global Bispecific Antibody Market Overview
7.1 Current Market Scenario
7.1.1 Catumaxomab (Removab)
7.1.2 Blinatumomab
7.1.3 Duligotumab
7.1.4 SAR 156597
7.2 Global Bispecific Antibodies Clinical Pipeline Overview

8. Global Bispecific Antibody Market Dynamics
8.1 Favorable Market Parameters
8.1.1 Target Patient Base
8.1.2 Severity Of The Disease
8.1.3 Unavailability Of Completely Curing Drugs
8.1.4 Side Effects of the Existing Drugs
8.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells
8.2 Commercialization Challenges
8.2.1 Stringent Regulatory Guidelines
8.2.2 Long Duration of Research & Development
8.2.3 Clinical Trial Timeline
8.2.4 High Cost for Research & Development

9. Global Bispecific Antibody Market Future Prospects

10. Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III

11. Marketed Bispecific Antibodies Clinical Insight
11.1 Blinatumomab (Blincyto)
11.2 Catumaxomab (Removab)

12. Discontinued & Suspended Bispecific Antibodies in Clinical Pipeline by Company, Indication & Phase
12.1 Discontinued
12.2 No Development Reported

13. Competitive Landscape
13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi

Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
Figure 3-2: Mechanism of Action of Catumaxomab
Figure 3-3: Mechanism of Action of Blinatumomab
Figure 4-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 4-2: Method of Formation of Hybrid Hybridoma
Figure 4-3: Limitations of Hybrid Hybridoma
Figure 4-4: Steps involved in “Knobs into Holes” Approach
Figure 4-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 4-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 4-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 4-8: Types of Bispecific Antibodies
Figure 5 1: Advantages of Bispecific Antibodies
Figure 6-1: Applications of Bispecific Antibodies
Figure 7-1: Global Bispecific Antibodies Pipeline by Phase (%), 2016
Figure 7-2: Global Bispecific Antibodies Pipeline by Phase (Numbers), 2016
Figure 7-3: Global Bispecific Antibodies Pipeline by Phase (%), 2016
Figure 7-4: Global Bispecific Antibodies Pipeline by Phase (Numbers), 2016
Figure 8-1: Favorable Market Parameters Global Bispecific Antibody Market
Figure 8-2: Commercialization Challenges for Bispecific Antibody
Figure 13-1: Ablynx - Clinical Pipeline
Figure 13-2: Affimed Therapeutics - Clinical Pipeline
Figure 13-3: Amgen - Clinical Pipeline
Figure 13-4: EMD Serono - Clinical Pipeline
Figure 13-5: Emergent Bioscience - Clinical Pipeline
Figure 13-6: Genmab - Clinical Pipeline
Figure 13-7: Jounce Therapeutics - Clinical Pipeline
Figure 13-8: MacroGenics - Clinical Pipeline
Figure 13-9: Merus - Clinical Pipeline
Figure 13-10: Novimmune - Clinical Pipeline
Figure 13-11: OncoMed - Clinical Pipeline
Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 13-13: Roche - Clinical Pipeline


Table 4-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
Table 4-2: List of Bispecific Antibodies Formed by DART
Table 4-3: List of Bispecific Antibodies Formed by BiTE Method
Table 4-4: List of Other BiTEs
Table 6-1: Bispecific Antibodies Targeting Cancer


【レポートのキーワード】

二重特異性抗体

★調査レポート[二重特異性抗体の世界市場及びパイプライン分析]販売に関する免責事項
★調査レポート[二重特異性抗体の世界市場及びパイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆